glp 1 drug shortage GLP-1 Shortages Compounding US FDA's Problems: The

Consequently, the development of new small molecules with the capacity to target mitochondria is anticipated to eradicate tumour stem cells

Longer half-life than ultra-short peptides like tesamorelin but shorter than growth hormone secretagogues like Ipamorelin (half-life ~2 hours but functional GH elevation lasting 68 hours)

Preliminary pharmacogenomic studies suggest that polymorphisms in GLP-1 receptor genes could influence both efficacy and tolerability, but clinical genetic testing is not currently recommended for routine practice

This may alleviate some burdens on healthcare systems and promote healthier communities